A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

ClinicalTrials.gov ID: NCT03744676

Public ClinicalTrials.gov record NCT03744676. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting

Study identification

NCT ID: NCT03744676
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Enrollment: 104 participants

Conditions and interventions

Conditions

Interventions

lisocabtagene maraleucel Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 28, 2018
Primary completion: Sep 21, 2023
Completion: Sep 21, 2023
Last update posted: Feb 26, 2025

2018 – 2023

United States locations

U.S. sites: 23
U.S. states: 17
U.S. cities: 23

Facility	City	State	ZIP	Site status
Local Institution - 0057	Los Angeles	California	90048	—
Local Institution - 0060	Denver	Colorado	80218	—
Local Institution - 0089	Miami	Florida	33176	—
Local Institution - 0081	Orlando	Florida	32804	—
Local Institution - 0065	Indianapolis	Indiana	46237	—
Local Institution - 0069	Wichita	Kansas	67124	—
Local Institution - 0064	Louisville	Kentucky	40207	—
Local Institution - 0101	Southfield	Michigan	48075	—
Local Institution - 0052	East Brunswick	New Jersey	08816	—
Local Institution - 0066	Morristown	New Jersey	07962	—
Local Institution - 0041	Albany	New York	12208	—
Local Institution - 0039	Cincinnati	Ohio	45236	—
Local Institution - 0098	Eugene	Oregon	97401	—
Local Institution - 0051	Portland	Oregon	97213	—
Lancaster General Hospital	Lancaster	Pennsylvania	17604	—
Local Institution - 0037	Greenville	South Carolina	29615	—
Local Institution - 0063	Nashville	Tennessee	37203	—
Local Institution - 0097	Dallas	Texas	75230	—
Local Institution - 0061	San Antonio	Texas	78229	—
Baylor Scott and White Health	Temple	Texas	76508	—
Local Institution - 0096	Tyler	Texas	75702	—
Local Institution - 0074	Salt Lake City	Utah	84143	—
Local Institution - 0036	Norfolk	Virginia	23502	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03744676, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 26, 2025 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03744676 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →